Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-75.71m
- Incorporated2012
- Employees17.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
More ▼
Mergers & acquisitions
| Acquired company | RLMD:NSQ since announced | Transaction value |
|---|---|---|
| Asarina Pharma AB-Sepranolone GABAA Neurosteroid | 51.84% | -- |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geovax Labs Inc | 5.59m | -24.50m | 18.38m | 17.00 | -- | 1.28 | -- | 3.29 | -4.21 | -4.21 | 0.7322 | 0.5707 | 0.788 | -- | -- | 328,908.30 | -345.27 | -128.86 | -616.17 | -172.81 | -- | -- | -438.17 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Rallybio Corp | 848.00k | -48.19m | 18.92m | 24.00 | -- | 0.3499 | -- | 22.31 | -1.08 | -1.08 | 0.019 | 1.30 | 0.0108 | -- | -- | 33,920.00 | -61.25 | -40.97 | -67.23 | -43.42 | -- | -- | -5,682.19 | -42,838.52 | -- | -- | 0.00 | -- | -- | -- | 22.52 | -- | -- | -- |
| OSR Holdings Inc | 761.27k | -13.74m | 19.28m | -- | -- | 0.2545 | -- | 25.32 | -1.73 | -1.73 | 0.1312 | 3.93 | 0.0072 | -- | -- | -- | -12.98 | -- | -19.82 | -- | 22.16 | -- | -1,805.31 | -- | 0.1966 | -- | 0.0344 | -- | -- | -- | -697.08 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -28.92m | 19.45m | 14.00 | -- | -- | -- | -- | -0.8003 | -0.8003 | 0.00 | -0.0954 | 0.00 | -- | -- | 0.00 | -281.12 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 23.79 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 5.21m | -27.12m | 19.53m | 21.00 | -- | -- | -- | 3.75 | -2.51 | -2.51 | 0.5661 | -1.39 | 0.589 | -- | -- | 247,904.80 | -306.82 | -80.94 | -- | -211.40 | -- | -- | -520.90 | -605.55 | -- | -0.911 | -- | -- | 18.54 | -3.61 | 2.54 | -- | 59.47 | -- |
| Relmada Therapeutics Inc | 0.00 | -75.71m | 19.75m | 17.00 | -- | 0.8802 | -- | -- | -2.50 | -2.50 | 0.00 | 0.6761 | 0.00 | -- | -- | 0.00 | -135.09 | -77.37 | -160.24 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
| Synlogic Inc | 0.00 | 2.56m | 19.77m | 1.00 | 7.59 | 1.51 | 7.71 | -- | 0.2226 | 0.2226 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | 9.49 | -44.41 | 13.42 | -50.06 | -- | -- | -- | -3,944.49 | -- | -- | 0.00 | -- | -99.76 | -67.55 | 61.88 | -- | -59.28 | -- |
| Goldenwell Biotech Inc | 140.00 | -134.91k | 19.80m | -- | -- | -- | -- | 141,428.60 | -0.0014 | -0.0014 | 0.00 | -0.0008 | 0.0007 | 0.0004 | -- | -- | -69.03 | -95.49 | -69.57 | -110.12 | 50.00 | 52.18 | -96,364.29 | -2,064.27 | 9.21 | -11.85 | -- | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Vyne Therapeutics Inc | 605.00k | -42.17m | 20.00m | 13.00 | -- | 0.434 | -- | 33.05 | -0.9898 | -0.9905 | 0.0142 | 2.77 | 0.0082 | -- | -- | 46,538.46 | -56.95 | -107.54 | -65.44 | -136.47 | -- | -- | -6,970.08 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 20.07m | 18.00 | -- | 1.41 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Cingulate Inc | 0.00 | -16.38m | 20.42m | 13.00 | -- | 3.10 | -- | -- | -10.21 | -10.21 | 0.00 | 1.55 | 0.00 | -- | -- | 0.00 | -182.32 | -157.80 | -324.15 | -303.36 | -- | -- | -- | -- | -- | -- | 0.4598 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -1.50m | 20.72m | 2.00 | -- | -- | -- | -- | -0.1454 | -0.1454 | 0.00 | -0.2227 | 0.00 | -- | -- | 0.00 | -716.40 | -- | -- | -- | -- | -- | -- | -- | -- | -10.67 | -- | -- | -- | -- | -78.73 | -- | -- | -- |
| Lisata Therapeutics Inc | 1.00m | -19.31m | 20.72m | 26.00 | -- | 0.8193 | -- | 20.72 | -2.30 | -2.30 | 0.119 | 2.94 | 0.0259 | -- | -- | 38,461.54 | -50.01 | -44.77 | -56.30 | -49.07 | -- | -- | -1,930.80 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.41m | 20.86m | 26.00 | -- | 2.60 | -- | -- | -0.0108 | -0.0108 | 0.00 | 0.0197 | 0.00 | -- | -- | 0.00 | -16.48 | -20.78 | -42.31 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.2651 | 0.6491 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -21.58m | 21.26m | 28.00 | -- | 2.82 | -- | -- | -2.49 | -2.49 | 0.00 | 0.2183 | 0.00 | -- | -- | 0.00 | -178.43 | -- | -2,314.78 | -- | -- | -- | -- | -- | -- | -26.71 | 0.2091 | -- | -- | -- | 18.49 | -- | -- | -- |
Data as of Jul 18 2025. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD
22.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Squadron Capital Management LLCas of 24 Apr 2025 | 2.05m | 6.79% |
| Acadian Asset Management LLCas of 31 Mar 2025 | 1.23m | 4.07% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 1.20m | 3.97% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 562.21k | 1.86% |
| Palo Alto Investors LPas of 31 Mar 2025 | 495.15k | 1.64% |
| Geode Capital Management LLCas of 31 Mar 2025 | 301.88k | 1.00% |
| Two Sigma Advisers LPas of 31 Mar 2025 | 288.00k | 0.95% |
| AdvisorShares Investments LLCas of 31 Mar 2025 | 276.51k | 0.92% |
| DWS Investments (UK) Ltd.as of 31 Mar 2025 | 224.85k | 0.75% |
| Two Sigma Investments LPas of 31 Mar 2025 | 170.54k | 0.57% |
More ▼
Data from 31 Mar 2025 - 24 Apr 2025Source: FactSet Research Systems Inc.
